Medical device company Zimmer Biomet (NYSE:ZBH) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7% year on year to $2.08 billion. Its non-GAAP profit of $2.07 per share was 4.8% above analysts’ consensus estimates.
Let's delve into the developments on the US markets one hour before the close of the markets on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.
Thursday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.
Zimmer Biomet (ZBH) offers steady dividends with 10+ years of payouts, strong profitability, and financial health, making it a reliable pick for long-term dividend investors.
Zimmer Biomet (ZBH) is a top value stock with strong profitability, low P/E ratios, and solid financial health—ideal for investors seeking undervalued healthcare opportunities.
Zimmer Biomet plans to acquire Monogram and integrate its robotic knee system into its ROSA platform to support growth and product expansion through 2027.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 6.3%. This drop is a far cry from the S&P 500’s 6.2% ascent.
ZIMMER BIOMET HOLDINGS INC (NYSE:ZBH) offers a reliable dividend with strong profitability and reasonable valuation, making it a candidate for income investors.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
ZIMMER BIOMET (NYSE:ZBH) is an undervalued medical device stock with strong profitability, a reasonable dividend, and improving growth prospects. A solid pick for value investors.
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
